Literature DB >> 26987948

Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.

Ming-Thau Sheu1, Chien-Ming Hsieh2, Ray-Neng Chen3, Po-Yu Chou1, Hsiu-O Ho4.   

Abstract

The aim of the present study was to prepare sublingual delivery systems for sildenafil and evaluate its relative bioavailability after sublingual administration in rabbits to attain a rapid onset of action with good efficacy at lower doses. For sublingual application, sildenafil and its citrate were formulated in 2 different dosage forms: the first was a sublingual spray consisting of sildenafil in 2 microemulsion systems, oleic acid or propylene glycol (PG), and the second was sublingual tablets prepared with various granulated sublingual sprays adsorbed onto a silicate adsorbant (Florite(®) R), binders (Cyclocel(®) or EMDEX(®)), and disintegrants (Ac-Di-Sol(®) or Kollidon(®) CL). Results showed that sublingual absorption of sildenafil spray prepared with PG was fairly rapid. At a 0.5-mg dose, the mean onset of action was 1.3 ± 0.6 min and lasted for about 1.5 h according to the pharmacokinetic studies. In vivo studies also showed that for sublingual tablets formulated with sildenafil in PG adsorbed onto Florite(®) R at a 1:1 weight ratio then mixed with Cycloel(®) and Ac-Di-Sol(®), the onset action was fast at 1.9 ± 0.4 min and lasted for about 1 h at 0.5 mg. These findings suggest the potential for the sublingual delivery of sildenafil instead of the conventional oral administration.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bioavailability; erectile dysfunction; sildenafil; sublingual spray; sublingual tablets

Mesh:

Substances:

Year:  2016        PMID: 26987948     DOI: 10.1016/j.xphs.2016.01.015

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use.

Authors:  Ousama Rachid; Mutasem Rawas-Qalaji; Keith J Simons
Journal:  Pharmaceutics       Date:  2018-02-11       Impact factor: 6.321

Review 2.  The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.

Authors:  A Zucchi; E Costantini; F I Scroppo; M Silvani; Z Kopa; E Illiano; M G Petrillo; L Cari; G Nocentini
Journal:  Andrology       Date:  2019-07-26       Impact factor: 3.842

Review 3.  Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era.

Authors:  Andreas Ouranidis; Anastasia Tsiaxerli; Elisavet Vardaka; Catherine K Markopoulou; Constantinos K Zacharis; Ioannis Nicolaou; Dimitris Hatzichristou; Anna-Bettina Haidich; Nikolaos Kostomitsopoulos; Kyriakos Kachrimanis
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-15

4.  Exploitation of Design-of-Experiment Approach for Design and Optimization of Fast-Disintegrating Tablets for Sublingual Delivery of Sildenafil Citrate with Enhanced Bioavailability Using Fluid-Bed Granulation Technique.

Authors:  Amer S AlAli; Mohammed F Aldawsari; Ahmed Alalaiwe; Bjad K Almutairy; Ramadan Al-Shdefat; Ismail A Walbi; Mohamed H Fayed
Journal:  Pharmaceutics       Date:  2021-06-12       Impact factor: 6.321

5.  Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study.

Authors:  Marianne J Naguib; Amal I A Makhlouf
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

6.  Sublingual indocyanine green films for non-invasive swallowing assessment and inflammation detection through NIR/SWIR optical imaging.

Authors:  André O'Reilly Beringhs; Surya Pratap Singh; Tulio Alberto Valdez; Xiuling Lu
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.